<DOC>
	<DOCNO>NCT00707707</DOCNO>
	<brief_summary>This first part 2-part study assess efficacy AZD2281 combination paclitaxel 1st 2nd line treatment patient metastatic triple negative breast cancer . This first part ( Phase I ) open-label , intra patient dose find study establish appropriate dos schedule paclitaxel AZD2281 combination , use randomize Phase II part . The safety tolerability AZD2281 combination paclitaxel explore . Approximately 10 patient per cohort 4-5 country enrol Phase I .</brief_summary>
	<brief_title>Phase I/II Study AZD2281 Given Combination With Paclitaxel Metastatic Triple Negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>patient histologically cytologically diagnose metastatic triple negative breast cancer ( Oestrogen , progesterone HER2 negative adenocarcinoma breast ) Patients must normal organ bone marrow function , ECOG performance status 2 Formalin fix , paraffin embed tumour sample primary recurrent cancer must available central test . Any chemotherapy , radiotherapy ( except palliative reason ) investigational product , within 2 week last dose prior study entry ( long period , depend agent use ) Major surgery within 4 week start study , must recover effect major surgery Patients require treatment follow : certain antibiotic drug , St.John 's Wort , carbamazepine , phenobarbitone , phenytoin , certain protease inhibitors/ nonnucleoside reverse transcriptase inhibitor use component HIV/AIDS treatment , Patients second primary cancer ; except adequately treat nonmelanoma skin cancer , curatively treated insitu cancer cervix , solid tumour curatively treat evidence disease least 5 year .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>triple negative</keyword>
	<keyword>metastatic</keyword>
</DOC>